Diethylstilbestrol Monobenzyl Ether

Diethylstilbestrol Monobenzyl Ether (DESMBE) is a synthetic, nonsteroidal estrogen that was researched for potential therapeutic applications but was never marketed. It is a derivative of diethylstilbestrol (DES), a drug that has been used in the past for various estrogenic treatments but has fallen out of favor due to its association with significant adverse effects, including an increased risk of certain cancers.

Chemistry

Diethylstilbestrol Monobenzyl Ether belongs to the group of stilbenes, which are chemical compounds characterized by a 1,2-diphenylethylene moiety. DESMBE is specifically a modified form of diethylstilbestrol where one of the ethyl groups is replaced with a benzyl ether group. This modification alters the compound's pharmacological properties, including its affinity and specificity for estrogen receptors.

Pharmacology

The pharmacological action of DESMBE, similar to other estrogens, involves the binding to and activation of the estrogen receptor (ER), a nuclear steroid hormone receptor that regulates the expression of genes involved in the control of reproductive and secondary sexual characteristics. The alteration in the chemical structure of DESMBE compared to DES was aimed at modifying its estrogenic activity, potentially reducing side effects or altering its therapeutic profile.

Clinical Applications and Research

Research into DESMBE was part of broader efforts to develop safer and more selective estrogenic compounds for use in hormone therapy, particularly for conditions like menopausal symptoms, osteoporosis, and certain hormone-responsive cancers. However, detailed information on the clinical research and potential applications of DESMBE is limited, as it did not progress to widespread clinical use.

Safety and Toxicology

The safety profile of DESMBE is not well-documented in the public domain, largely because it did not enter extensive clinical use. However, given its structural and pharmacological similarity to diethylstilbestrol, there would be concerns about its potential to cause similar adverse effects, such as an increased risk of certain cancers and reproductive issues. The history of DES and its link to serious health issues, including a rare vaginal cancer in daughters of women who took DES during pregnancy, would necessitate rigorous safety evaluations of any related compounds like DESMBE.

Regulatory Status

As of the last available information, Diethylstilbestrol Monobenzyl Ether has not been approved for medical use by any major regulatory body, including the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). The compound remains of interest primarily for historical and research purposes, particularly in studies exploring the structure-activity relationships of synthetic estrogens.

Conclusion

Diethylstilbestrol Monobenzyl Ether represents a chapter in the ongoing search for effective and safe estrogenic compounds for therapeutic use. While it did not achieve clinical application, its development and study contribute to the broader understanding of synthetic estrogens and their potential impacts on human health.

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian